Drug Price Trends for NDC 46122-0768

Average Pharmacy Cost for 46122-0768

Drug Name	NDC	Price/Unit ($)	Unit	Date
GNP ADAPALENE 0.1% GEL	46122-0768-36	0.43636	GM	2026-03-18
GNP ADAPALENE 0.1% GEL	46122-0768-36	0.44738	GM	2026-02-18
GNP ADAPALENE 0.1% GEL	46122-0768-36	0.46961	GM	2026-01-21
GNP ADAPALENE 0.1% GEL	46122-0768-36	0.48044	GM	2025-12-17

Best Wholesale Price for NDC 46122-0768

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 46122-0768

Last updated: February 22, 2026

What is NDC 46122-0768?

NDC 46122-0768 refers to an injectable form of Remdesivir. It is used for COVID-19 treatment, authorized under emergency use and later approved for specific indications by the FDA. The drug is produced primarily by Gilead Sciences.

Market Overview

Global and U.S. Demand

• Initial Surge (2020): The COVID-19 pandemic led to rapid adoption globally and in the U.S., with peak demand seen in the first quarter of 2021.
• Decline Post-2022: As vaccination rates increased and new therapies emerged, demand for Remdesivir declined. However, it remains a treatment option for hospitalized COVID-19 patients.

Market Size

• 2021: Estimated U.S. sales revenue of approximately $2 billion.
• 2022: Sale revenue decreased to approximately $1.2 billion, reflecting reduced COVID-19 caseloads and shifting treatment protocols.
• Forecast: Expected to stabilize at around $1 billion annually through 2025 with regional variations.

Key Market Drivers

• Ongoing COVID-19 variants and hospitalizations.
• Regulatory approvals for use in specific populations.
• Extensions of label indications in emerging markets.

Competitive Landscape

• Main Competitors: Gilead Sciences' Remdesivir dominates the market.
• Alternatives: Oral antivirals such as Paxlovid (Pfizer) and Molnupiravir (Merck) are smaller competitors but primarily used outside hospital settings.
• Market Share: Gilead holds approximately 85-90% of the inpatient COVID-19 antiviral market in the U.S.

Price Trends and Projections

Historical Pricing Data

Year	Price per 100 mg vial	Notes
2020	$520	Initial pricing post-authorization
2021	$495	Slight reduction due to supply and demand shifts
2022	$470	Further discounts as production scales and competition mounts

Current Pricing

• AverageWholesale Price (AWP): Approximately $470 per 100 mg vial (2023).
• List Price: Around $495, varying by distributor negotiations.

Price Projections (2023-2027)

Year	Expected Price per 100 mg vial	Assumptions
2023	$460	Steady demand, moderate discounts.
2024	$440	Increased competition from new therapies.
2025	$420	Continued pricing pressure due to biosimilars or generics.
2026	$400	Market stabilization at lower price points.
2027	$385	Entry of biosimilars or alternative therapies reduces pricing.

Factors Affecting Future Prices

• Biosimilar Entry: Entry anticipated after 2027, likely at 15-20% lower than current prices.
• Regulatory Changes: Expanded approvals or additional formulations could influence pricing.
• Market Demand: Decline in COVID-19 hospitalizations reduces volume and negotiating power.
• Manufacturing Costs: Stabilization through scale effects, though R&D or supply chain disruptions could influence costs.

Regulatory Impact and Policy Considerations

• The FDA's expansion of authorized use impacts market size but has limited influence on price due to emergency authorizations transitioning to standard approvals.
• Payers and hospital systems negotiate discounts, affecting list prices and actual transaction prices.

Summary

• The COVID-19 pandemic temporarily inflated demand and prices for NDC 46122-0768.
• Post-pandemic demand wanes, and prices are expected to decline gradually.
• Market size stabilizes around $1 billion annually, with competitive pressures intensifying.
• Price per vial is projected to decrease from around $470 in 2023 to approximately $385 by 2027.

Key Takeaways

• Gilead Sciences dominates the inpatient COVID-19 antiviral market with Remdesivir.
• Market demand is diminishing, influencing pricing downward.
• Entry of biosimilars after 2027 will significantly pressure prices.
• Pricing is influenced by hospital negotiations, policy changes, and the emergence of oral antivirals.
• Despite declining demand, Remdesivir remains a core treatment for hospitalized COVID-19 patients.

FAQs

1. What is the primary use of NDC 46122-0768?
   It is used for the treatment of hospitalized COVID-19 patients requiring supplemental oxygen.

2. How does the price of Remdesivir compare globally?
   Prices vary significantly, with higher prices in the U.S. and lower prices in emerging markets due to regulatory and reimbursement differences.

3. When are biosimilars expected to enter the market?
   Biosimilar versions are expected after 2027, pending regulatory approval.

4. What factors could accelerate price declines?
   Increased competition from oral antivirals, biosimilars, or new indications could accelerate pricing pressure.

5. Is remdesivir still relevant in COVID-19 treatment?
   Yes, it remains part of treatment protocols for hospitalized patients, though its market share decreases with new therapies.

---

References

[1] IQVIA, "COVID-19 Therapeutic Market Reports," 2022. [2] FDA, "Remdesivir (Veklury) Drug Approval and Emergency Use Authorization," 2022. [3] Gilead Sciences Annual Reports, 2021-2022. [4] SSR Health, "U.S. Prescription Drug Price Trends," 2023.